Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 8/20 | 0.70 |
| ▸ | KDR | P35968 | 2/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.52 |
| ▸ | KIT | P10721 | 3/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3978525 | 0.82 | BRAF (1.00) | BRAFKDRPDGFRBPTGS1KCNK3 | |
| SCHEMBL3977917 | 0.81 | JAK3 (0.64) | BRAFKDRPDGFRBPTGS1KCNK3 | |
| SCHEMBL3982343 | 0.79 | BRAF (1.00) | BRAFKDRPDGFRBPTGS1KCNK3 | |
| SCHEMBL4195360 | 0.78 | BRAF (0.71) | BRAFKDRPDGFRBKCNK3MAPT | |
| SCHEMBL4194960 | 0.77 | BRAF (0.70) | BRAFKDRPDGFRBPTGS1KCNK3 | |
| SCHEMBL3980014 | 0.76 | BRAF (0.73) | BRAFKDRPDGFRBPTGS1KCNK3 | |
| SCHEMBL4200345 | 0.76 | BRAF (1.00) | BRAFKDRPDGFRBMAPTRXFP1 | |
| SCHEMBL4205684 | 0.75 | BRAF (0.88) | BRAFKDRPDGFRBPTGS1KCNK3 | |
| SCHEMBL2305033 | 0.75 | LCK (0.53) | BRAFKDRPDGFRBKITPTGS1 | |
| SCHEMBL3983734 | 0.74 | BRAF (0.59) | BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118276-A1 | THIENOPYRIMIDINES, THIENOPYRIDINES, AND PYRROLOPYRIMIDINES AS B-RAF INHIBITORS | WYETH (US) | 2009-05-07 | — | — | US | disclosed |
| WO-2009059272-A1 | THIENOPYRIMIDINES, THIENOPYRIDINES, AND PYRROLOPYRIMIDINES AS B-RAF INHIBITORS | WYETH (US) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118276-A1 | THIENOPYRIMIDINES, THIENOPYRIDINES, AND PYRROLOPYRIMIDINES AS B-RAF INHIBITORS | BRAF, ARAF, RAF1 | BRAF 1/4885KDR 616/4885PDGFRB 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.